John L. Higgins
Net Worth
Last updated:
What is John L. Higgins net worth?
The estimated net worth of Mr. John L. Higgins is at least $131,390,923 as of 16 Dec 2022. He owns shares worth $63,045,765 as insider, has earned $47,105,158 from insider trading and has received compensation worth at least $21,240,000 in Ligand Pharmaceuticals Incorporated.
What is the salary of John L. Higgins?
Mr. John L. Higgins salary is $1,180,000 per year as Chief Executive Officer & Executive Director in Ligand Pharmaceuticals Incorporated.
How old is John L. Higgins?
Mr. John L. Higgins is 55 years old, born in 1970.
What stocks does John L. Higgins currently own?
As insider, Mr. John L. Higgins owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | Chief Executive Officer & Executive Director | 422,984 | $149.05 | $63,045,765 |
What does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
John L. Higgins insider trading
Ligand Pharmaceuticals Incorporated
Mr. John L. Higgins has made 32 insider trades between 2007-2022, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of LGND stock worth $618,660 on 16 Dec 2022.
The largest trade he's ever made was exercising 114,666 units of LGND stock on 5 Feb 2021. As of 16 Dec 2022 he still owns at least 422,984 units of LGND stock.
Ligand Pharmaceuticals Incorporated key executives
Ligand Pharmaceuticals Incorporated executives and other stock owners filed with the SEC:
- Mr. Charles S. Berkman (56) Senior Vice President, Gen. Counsel & Sec.
- Mr. John L. Higgins (55) Chief Executive Officer & Executive Director
- Mr. Matthew E. Korenberg (50) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Matthew W. Foehr (52) Pres & Chief Operating Officer